Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of recombinant botulinum toxin type A injection for moderate to severe glabellar lines
CTR20233901Phase 3Completed
- Sponsor
- Yuyan Pharma
- Start
- Dec 2023
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of JHM03 in glabellar furrowing (3 arms), sponsored by Yuyan Pharma. Primary endpoint: Composite responder rate for improvement in glabellar line severity at maximum frown (investigator and subject assessed). Started Dec 2023; status: completed.
02
Drugs
JHM03
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20233901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233901.